Challenges and Solutions to Immunosuppressant Therapy Drug Discovery & Development The primary efficacy endpoint was a composite of death, graft failure, biopsy-proven acute rejection (BPAR) via a local pathology reading or loss to follow-up within 12 months of randomization. LCP-Tacro demonstrated a trend toward lower rejection ... |
